Tags : Relapsing-Remitting

Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting

Shots: Roche divulges new data that demonstrate Ocrevus (ocrelizumab) is a highly effective treatment option for people with RRMS who experienced a suboptimal response to their prior DMT. In open-label P-IIIb CASTING study, 75% of patients with RRMS and suboptimal response to prior treatment had no evidence of disease activity 2yrs. after switching to Ocrevus […]Read More